Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COGNITION THERAPEUTICS INCCGTX · Entity 6792 | Interim CFO | August 12, 2022 | August 15, 2022 |
| PDS Biotechnology CorpEDGE · Entity 7939 | Chief Financial Officer | March 01, 2017 | March 13, 2017 |
| Pelthos Therapeutics Inc.PTHS · Entity 6798 | Director | December 23, 2025 | December 29, 2025 |
| RVL Pharmaceuticals plcRVLP · Entity 108806 | Chief Financial Officer | January 24, 2022 | January 26, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COGNITION THERAPEUTICS INC
Report date August 12, 2022 · Filed August 15, 2022
This filing explicitly reported no securities owned.
PDS Biotechnology Corp
Report date March 01, 2017 · Filed March 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,223 |
Reported balance
After 2017-03-01 transaction · row 1
1 source rowRow 1 · 2017-03-01 · Other · Acquired 1,567 · Balance 43,223 |
| Warrants (right To Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.39 · Expires 2017-09-09 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Other · Disposed 1,567 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Harpua, Llc | 83,592 |
Reported balance
Holding disclosure · report date 2017-03-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83,592 F1: The Reporting Person is the sole managing member of Harpua, LLC and may be deemed to beneficially own these shares. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the sole managing member of Harpua, LLC and may be deemed to beneficially own these shares. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Pelthos Therapeutics Inc.
Report date December 23, 2025 · Filed December 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,000 |
Reported balance
After 2025-12-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-23 · Grant · Acquired 12,000 · Balance 12,000 F1: On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share.
RVL Pharmaceuticals plc
Report date January 24, 2022 · Filed January 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 141,473 |
Reported balance
After 2022-01-24 transaction · row 1
1 source rowRow 1 · 2022-01-24 · Tax withholding · Disposed 9,607 · Balance 141,473 |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy family limited liability company | 22,852 |
Reported balance
Holding disclosure · report date 2022-01-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,852 F1: The Reporting Person is the sole managing member of the limited liability company and, as a result, may be deemed to beneficially own the ordinary shares held by the limited liability company. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the sole managing member of the limited liability company and, as a result, may be deemed to beneficially own the ordinary shares held by the limited liability company. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 23, 2025 Filed Dec 29, 2025 16:16 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantCommon Stock | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001753926-25-001991 · ownership.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F1 · security: On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share. F1 · price: On December 23, 2025, the Reporting Person was granted 12,000 Restricted Stock Units (the "RSUs") of the issuer, as compensation for the Reporting Person's service as a member of the issuer's board of directors, pursuant to the issuer's 2023 Equity Incentive Plan, as amended and restated effective as of April 16, 2025 (the "Plan"). The RSUs will vest on January 1, 2027. Each RSU represents a contingent right to receive one share of issuer's Common Stock, par value $0.0001 per share. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 16:31 UTC | RVL Pharmaceuticals plc RVLP · Entity 108806 | Tax withholdingOrdinary Shares | 9,607 | $1.13 | $10,855.91 |
DisclosureSEC source: 0001104659-22-007844 · tm223506-4_4seq1.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,473 Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 16:06 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantShare Option (Right to Buy) · Derivative | 249,814 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001104659-21-135637 · tm2132232-2_4seq1.xml · derivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,814 Underlying: Ordinary Shares · 249,814 shares Expires 2031-11-04 F1 · derivative.exercise_date: The option vests as to 25% of the ordinary shares underlying the award on the first anniversary of the grant and as to the remaining 75% of the shares in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:06 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | Tax withholdingOrdinary Shares | 6,467 | $3.12 | $20,177.04 |
DisclosureSEC source: 0001104659-21-069879 · tm2117061-1_4seq1.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,080 Read SEC document |
| January 24, 2021 Filed Jan 26, 2021 19:02 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | Tax withholdingOrdinary Shares | 9,668 | $4.46 | $43,119.28 |
DisclosureSEC source: 0001104659-21-007785 · tm214203-3_4seq1.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,547 Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:48 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantPerformance-Based Restricted Stock Units · Derivative | 71,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064440 · a4.xml · derivative · entry 3 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Ordinary Shares · 71,550 shares Expires not disclosed F3 · derivative.exercise_price: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II. F3 · derivative.exercise_date: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II. F3 · derivative.expiration_date: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II. F3 · derivative.underlying_shares: The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:48 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantOrdinary Shares | 71,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-064440 · a4.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,215 F1 · kind: Represents a grant of restricted stock units. F1 · shares: Represents a grant of restricted stock units. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 17:38 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | Tax withholdingOrdinary Shares | 9,184 | $7.00 | $64,288.00 |
DisclosureSEC source: 0001104659-20-008837 · a4.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,665 Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 17:49 UTC | RVL Pharmaceuticals plc OSMT · Entity 108806 | GrantOrdinary Shares | 104,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-003723 · a4.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,849 F1 · kind: Represents a grant of restricted stock units. F1 · shares: Represents a grant of restricted stock units. Read SEC document |
| March 01, 2017 Filed Mar 13, 2017 17:47 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | OtherWarrants (right To Purchase) · Derivative | 1,567 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001127602-17-011377 · form4.xml · derivative · entry 3 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,567 shares Expires 2017-09-09 Read SEC document |
| March 01, 2017 Filed Mar 13, 2017 17:47 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | OtherCommon Stock | 1,567 | $2.39 | $3,745.13 |
DisclosureSEC source: 0001127602-17-011377 · form4.xml · nonDerivative · entry 1 Einhorn Andrew J. · CIK 0001560685 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,223 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.